BRISTOL-MYERS SQUIBB COMPANY (BMY) Quick Ratio
- Quick ratio · latest quarter: Value 1.08×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.08× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $20.14B ÷ $18.66B ≈ 1.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 20.14B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 18.66B USD | Liabilities, Current |
| Cash and equivalents | 8.72B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.35B USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 9.08B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 2.74B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.14B | $18.66B | $8.72B | $2.35B | $9.08B | $2.74B | 1.08× |
| 2026-03-31 | $18.43B | $19.16B | $9.57B | $912.00M | $7.95B | $2.76B | 0.96× |
| 2025-12-31 | $20.27B | $23.42B | $10.21B | $464.00M | $9.59B | $2.69B | 0.87× |
| 2025-09-30 | $26.13B | $28.14B | $15.73B | $776.00M | $9.62B | $2.76B | 0.93× |
| 2025-06-30 | $23.31B | $27.53B | $12.60B | $1.00B | $9.71B | $2.74B | 0.85× |
| 2025-03-31 | $20.84B | $24.07B | $10.88B | $907.00M | $9.06B | $2.67B | 0.87× |
| 2024-12-31 | $19.87B | $23.77B | $10.35B | $513.00M | $9.01B | $2.56B | 0.84× |
| 2024-09-30 | $17.41B | $22.64B | $7.89B | $204.00M | $9.32B | $3.33B | 0.77× |
| 2024-06-30 | $16.40B | $23.27B | $6.29B | $360.00M | $9.75B | $3.08B | 0.70× |
| 2024-03-31 | $18.50B | $25.82B | $9.33B | $340.00M | $8.83B | $2.98B | 0.72× |
| 2023-12-31 | $21.16B | $22.26B | $11.46B | $816.00M | $8.88B | $2.66B | 0.95× |
| 2023-09-30 | $16.09B | $23.46B | $7.51B | $171.00M | $8.41B | $2.44B | 0.69× |
| 2023-06-30 | $16.86B | $20.15B | $8.37B | $358.00M | $8.13B | $2.36B | 0.84× |
| 2023-03-31 | $17.12B | $19.09B | $8.99B | $274.00M | $7.85B | $2.60B | 0.90× |
| 2022-12-31 | $17.40B | $21.89B | $9.12B | $130.00M | $8.15B | $2.34B | 0.80× |
| 2022-09-30 | $17.05B | $18.93B | $7.73B | $1.29B | $8.02B | $2.07B | 0.90× |
| 2022-06-30 | $20.81B | $20.91B | $10.75B | $2.48B | $7.59B | $2.14B | 1.00× |
| 2022-03-31 | $22.12B | $22.82B | $12.37B | $2.60B | $7.16B | $2.10B | 0.97× |
| 2021-12-31 | $24.95B | $21.87B | $13.98B | $2.99B | $7.98B | $2.10B | 1.14× |
| 2021-09-30 | $23.54B | $21.46B | $13.54B | $2.12B | $7.88B | $2.16B | 1.10× |
| 2021-06-30 | $20.68B | $18.99B | $11.02B | $1.95B | $7.71B | $2.14B | 1.09× |
| 2021-03-31 | $20.12B | $17.33B | $10.98B | $1.95B | $7.19B | $1.95B | 1.16× |
| 2020-12-31 | $23.05B | $19.08B | $14.55B | $1.28B | $7.22B | $2.07B | 1.21× |
| 2020-09-30 | $27.93B | $20.46B | $19.43B | $1.72B | $6.78B | $1.95B | 1.36× |
| 2020-06-30 | $28.36B | $23.42B | $19.93B | $1.72B | $6.70B | $2.38B | 1.21× |
| 2020-03-31 | $25.52B | $19.23B | $15.82B | $2.50B | $7.20B | $2.84B | 1.33× |
| 2019-12-31 | $21.87B | $18.30B | $12.35B | $3.05B | $6.48B | $4.29B | 1.19× |
| 2019-09-30 | $36.83B | $10.49B | $30.49B | $2.05B | $4.29B | $1.19B | 3.51× |
| 2019-06-30 | $33.86B | $9.71B | $28.40B | $953.00M | $4.50B | $1.31B | 3.49× |
| 2019-03-31 | $13.36B | $8.84B | $7.33B | $1.43B | $4.59B | $1.28B | 1.51× |
| 2018-12-31 | $13.52B | $10.65B | $6.91B | $1.97B | $4.64B | $1.20B | 1.27× |
| 2018-09-30 | $11.45B | $9.69B | $5.41B | $1.42B | $4.62B | $1.28B | 1.18× |
| 2018-06-30 | $10.40B | $9.88B | $5.00B | $1.08B | $4.32B | $1.24B | 1.05× |
| 2018-03-31 | $11.14B | $9.62B | $5.34B | $1.43B | $4.37B | $1.23B | 1.16× |
| 2017-12-31 | $11.16B | $9.56B | $5.42B | $1.39B | $4.35B | $1.17B | 1.17× |
| 2017-09-30 | $11.45B | $9.44B | $4.64B | $2.48B | $4.33B | $1.25B | 1.21× |
| 2017-06-30 | $10.72B | $9.02B | $3.47B | $3.04B | $4.22B | $1.22B | 1.19× |
| 2017-03-31 | $10.19B | $8.49B | $3.91B | $2.20B | $4.08B | $1.38B | 1.20× |
| 2016-12-31 | $10.12B | $8.84B | $4.24B | $2.11B | $3.77B | $1.24B | 1.15× |
| 2016-09-30 | $9.37B | $9.00B | $3.43B | $2.13B | $3.81B | $1.48B | 1.04× |
| 2016-06-30 | $8.34B | $7.88B | $2.93B | $1.72B | $3.69B | $1.44B | 1.06× |
| 2016-03-31 | $7.67B | $7.60B | $2.64B | $1.66B | $3.36B | $1.34B | 1.01× |
| 2015-12-31 | $7.22B | $8.02B | $2.38B | $1.89B | $2.95B | $1.22B | 0.90× |
| 2015-09-30 | $8.13B | $7.16B | $3.98B | $1.44B | $2.71B | $1.13B | 1.14× |
| 2015-06-30 | $8.02B | $7.43B | $4.20B | $1.28B | $2.54B | $1.30B | 1.08× |
| 2015-03-31 | $9.86B | $7.69B | $6.29B | $1.31B | $2.25B | $1.44B | 1.28× |
| 2014-12-31 | $9.54B | $8.46B | $5.57B | $1.86B | $2.10B | $1.56B | 1.13× |
| 2014-09-30 | $9.04B | $8.10B | $4.85B | $2.37B | $1.82B | $1.56B | 1.12× |
| 2014-06-30 | $8.97B | $7.80B | $4.28B | $2.89B | $1.80B | $1.67B | 1.15× |
| 2014-03-31 | $8.80B | $7.52B | $5.22B | $1.83B | $1.74B | $1.66B | 1.17× |
| 2013-12-31 | $6.21B | $12.44B | $3.59B | $939.00M | $1.69B | $1.50B | 0.50× |
| 2013-09-30 | $4.56B | $8.28B | $1.77B | $951.00M | $1.84B | $1.64B | 0.55× |
| 2013-06-30 | $4.65B | $8.35B | $1.82B | $978.00M | $1.85B | $1.78B | 0.56× |
| 2013-03-31 | $4.33B | $8.41B | $1.35B | $1.18B | $1.80B | $1.79B | 0.51× |
| 2012-12-31 | $4.54B | $8.28B | $1.66B | $1.17B | $1.71B | $1.66B | 0.55× |
| 2012-09-30 | $4.66B | $8.20B | $1.50B | $1.43B | $1.73B | $1.70B | 0.57× |
| 2012-06-30 | $6.66B | $6.99B | $2.80B | $2.24B | $1.62B | $1.52B | 0.95× |
| 2012-03-31 | $7.28B | $7.21B | $2.31B | $2.72B | $2.25B | $1.46B | 1.01× |
| 2011-12-31 | $10.98B | $7.78B | $5.78B | $2.96B | $2.25B | $1.38B | 1.41× |
| 2011-09-30 | $10.37B | $7.31B | $4.47B | $3.72B | $2.18B | $1.36B | 1.42× |
| 2011-06-30 | $9.79B | $7.41B | $3.67B | $4.00B | $2.12B | $1.49B | 1.32× |
| 2011-03-31 | $8.84B | $6.75B | $3.40B | $3.39B | $2.05B | $1.32B | 1.31× |
| 2010-12-31 | $9.29B | $6.74B | $5.03B | $2.27B | $1.99B | $1.20B | 1.38× |
| 2010-09-30 | $10.32B | $6.28B | $7.58B | $778.00M | $1.97B | $1.37B | 1.64× |
| 2010-06-30 | $9.26B | $5.91B | $5.92B | $1.54B | $1.80B | $1.26B | 1.57× |
| 2010-03-31 | (m) | $6.02B | $5.13B | $1.64B | (m) | $1.28B | (m) |
| 2009-12-31 | (m) | $6.31B | $7.68B | $831.00M | (m) | $1.41B | (m) |
| 2009-09-30 | (m) | $7.39B | $6.37B | $302.00M | (m) | $1.82B | (m) |
| 2009-06-30 | (m) | $6.74B | $7.51B | $613.00M | (m) | $1.78B | (m) |
| 2009-03-31 | (m) | (m) | $7.83B | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $6.71B | $7.98B | $289.00M | (m) | $1.76B | (m) |
| 2008-09-30 | (m) | (m) | $7.17B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $4.05B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $1.80B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $2.02B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |